Sentences with phrase «immune cells from a patient»

In theory, scientists could remove immune cells from a patient, run them through the microfluidic device and expose them to a viral protein, and then put them back in the patient.

His laboratory has developed a number of techniques to study the molecular profiles of circulating and airway immune cells from patients with asthma and other diseases, using fewer cells than was possible previously.

Staff at the clinic will take these immune cells from a patient, have the cells specially engineered in a nearby Hutch cell - processing facility, and then re-infuse them to attack the patient's cancer.

Not exact matches

Consider: Last year alone, the FDA approved two treatments, from Novartis and Gilead, that literally reengineer patients» immune T - cells to target and destroy blood cancers.

The company is developing a T - cell reprogramming technology designed to generate an anti-tumor response from the patient's own immune system.

Speaking of Novartis — the company's experimental CTL019, which is expected to be the first approved drug in a revolutionary new cancer treatment space that turns the body's own immune cells into cancer - killers, is already facing some apprehension from doctors and patient groups who are worried about its eventual pricing.

«But at some point we'll be able fabricate a biodevice from a patient's own cells that will duplicate the most important functions of a kidney and that won't be rejected by the patient's immune system.»

This new kind of approach to fighting blood cancers is truly personalized; immune T - cells are extracted from patients, genetically tinkered to home in on an destroy cancerous cells, multiplied in a lab, and then jolted back into the patient's body within about two weeks.

And using cells from someone other than the cancer patient being treated might trigger an immune response against the foreign cells.

The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of GVHD.

Based on these ex vivo experiments (in cells isolated from patients and then exposed to PD - L1 blocking agents outside of the body), they predict that when actual patients are given PD - L1 blocking agents, their viral load at the time will influence the «net» outcome, i.e., whether the blockage boosts or weakens the overall anti-HIV immune response.

Normally, this protein prevents immune cells from attacking an patient's own body.

The Boston patients, in contrast, are free of the virus thanks to a combination of a bone marrow transplant plus continuing antiretroviral drugs to stop newly donated immune cells from being infected.

HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumor samples and discovered that specialized immune cells in brain tumor patients are compromised.

«Cardiac stem cells from heart disease patients may be harmful: Researchers discover molecular pathway involved in toxic interaction between host cells and immune system.»

Lu's team will extract immune cells called T cells from the blood of the enrolled patients, and then use CRISPR — Cas9 technology — which pairs a molecular guide able to identify specific genetic sequences on a chromosome with an enzyme that can snip the chromosome at that spot — to knock out a gene in the cells.

The new findings build on prior research from the Dhodapkar lab demonstrating that patients with Gaucher disease, an inherited lipid storage disorder, have a significant increased risk for developing myeloma; and the discovery of a subset of lipid - reactive immune cells, called type II NKT - TFH, that promote the development of plasma cells.

«If you give patients immune cells to eradicate any remaining cancer cells that might be present,» he says, «those immune cells would not be prevented from doing their job by ongoing immune suppression drugs that are being used in patients treated with conventional transplant approaches.»

From a simple blood draw, the test reads the DNA of the patient's immune repertoire to find the immune cell barcodes associated with the cancer.

Researchers are developing many different versions of CAR - T cell therapies, but the basic premise is the same: Doctors remove a patient's T cells (immune system cells that attack invaders) from a blood sample and genetically modify them to produce artificial proteins on their surfaces.

The cells were derived from eggs that had been injected with DNA from the patients, so they could eventually be transplanted back to replace or correct the patient's diseased cells without fear of immune rejection.

The researchers then took naïve immune cells — which transform into different types based on the invaders they encounter — from the blood of healthy individuals and exposed them to bacteria in the guts of MS patients.

Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.

The personalized vaccine is made from patients» own immune cells, which are exposed in the laboratory to the contents of the patients» tumor cells, and then injected into the patients to initiate a wider immune response.

Next, the team exposed immature immune cells from the blood of healthy people to the bacteria found in the guts of MS patients.

«Compared to blood from the same patients, the inflamed joint immune cells were much less sensitive to active vitamin D.

«We therefore investigated responses to the active form of vitamin D in immune cells from the inflamed joints of patients with rheumatoid arthritis.

«This appears to be because immune cells from the joints of rheumatoid arthritis patients are more committed to inflammation, and therefore less likely to change, even though they have all the machinery to respond to vitamin D.»

It has been understood for several years that, in patients suffering from this disease, immune cells attack the aquaporin - 4 water channel of the brain cells.

To manufacture CAR T cells, scientists extract bone marrow from a patient, introduce genetic instructions for a CAR into the T cells, and then infuse those engineered immune cells back into the person's bloodstream.

Injected mRNAs normally would be cleared from the body within minutes by a patient's immune system, but these mRNAs are modified so that they are ignored by the immune system and can easily enter cells.

Patients could benefit from having their own cells reprogrammed into ones that could help treat disease, potentially eliminating the prospect of immune rejection.

Furthermore, they have found that neural stems cells can be culled from the patient's bone marrow, thus circumventing ethical and political obstacles to neural stem cell therapy as well as problems with immune rejection that sometimes arise when researchers must employ embryonic stem cell lines.

The researchers also analyzed specific immune cells called cytotoxic T cells isolated from the patients» blood and found increases in biomarkers indicative of immune activation.

These vulnerable patients, whose immune defenses have taken a dramatic double hit from both their original disease and the treatments required to repopulate their immune system with donor cells, are especially susceptible to a wide range of infections that typically don't cause major problems in healthy people.

Next, T cells — the immune system's foot soldiers — are harvested from the patient's blood and infected with the virus, which rewrites their genetic code to recognize and destroy cancer cells.

This time, instead of using skin cells, the team reprogrammed lymphocytes (immune cells) from six entirely new bipolar patients, some of whom are known lithium responders.

He is pioneering a new treatment for autoimmune disorders, one in which patients» immune systems are suppressed and then replaced with an infusion of their own immune stem cells, filtered out from their blood.

Monitoring immune cell activity — including phenotyping immune cell subsets, tracking cell proliferation, and measuring cytokine production — can provide insights into the overall status of immune function in patients, particularly those undergoing immunosuppression after transplants, enduring cancer treatment, or suffering from autoimmune disease or other pathologies that affect the immune system.

Effector T cells incite GvHD when they become overactive as the patient's immune system starts to rebuild itself from the donor stem cells.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

Instead, the vaccines use killed autologous tumor cells from the patient to activate the immune system.

Transplanted embryonic stem cells are ethically cleaner, but they have a genetic makeup different from the patient's own, so they could be violently rejected by the immune system.

Recently, scientists have engineered cells from a patient's own immune system to fight blood cancers.

A number of new clinical trials aim to take cells from a patient, such as blood cells or immune cells, edit them and transfer them back with new power to undermine diseases like cancer or sickle cell anemia.

In patients with severe asthma, however, NK cells are disabled from resolving inflammation, and become outnumbered by other types of immune cells that provoke inflammation.

«Protection for the gut barrier: New approach may prevent graft - versus - host disease: Activating signal paths could protect patients from dangerous immune reactions after stem cell transplantations.»

If CTL019 is approved, the Swiss pharmaceutical giant plans to dole it out from about 30 preapproved sites, each trained in the multi-step process of harvesting cells, handling the product, and treating patients for the feverish and often life - threatening immune response that usually accompanies CAR - T therapy.

The immune activation from the CAR cells was also met with resistance mechanisms, including an upregulation of immunosuppressive pathways which may work against the patient and for the tumor, the researchers found.

If some of those cells could be removed from a person with AIDS, genetically engineered to be resistant, and then returned to the patient, they might spawn an immune system that is completely resistant to the disease.